Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication

Alexion has scored an additional FDA OK for its keystone rare therapy Soliris, unlocking what a key analyst calls a significant part of its C5 franchise and elevating that portfolio further up the blockbuster ranks.